Moreover, the loss of SNHG6 expression was responsible for mTORC1 signaling inhibition and the growth impairment of PDX liver tumors, promoting SNHG6 as a promising biomarker for developing HCC targeted therapies [231]. This evidence concerns the gene SNHG6 and hepatocellular carcinoma.